Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax® tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study.
Drug Des Devel Ther
; 11: 2109-2119, 2017.
Article
em En
| MEDLINE
| ID: mdl-28744102
ABSTRACT
PURPOSE:
The aim of this study was to evaluate the bioequivalence of a generic product 70 mg alendronate sodium tablets with the reference product Fosamax® 70 mg tablet. MATERIALS ANDMETHODS:
A single-center, open-label, randomized, three-period, three-sequence, reference-replicated crossover study was performed in 36 healthy Chinese male volunteers under fasting conditions. In each study period, the volunteers received a single oral dose of the generic or reference product (70 mg). Blood samples were collected at pre-dose and up to 8 h after administration. The bioequivalence of the generic product to the reference product was assessed using the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) reference-scaled average bioequivalence (RSABE) methods.RESULTS:
The average maximum concentrations (Cmax) of alendronic acid were 64.78±43.76, 56.62±31.95, and 60.15±37.12 ng/mL after the single dose of the generic product and the first and second doses of the reference product, respectively. The areas under the plasma concentration-time curves from time 0 to the last timepoint (AUC0-t ) were 150.36±82.90, 148.15±85.97, and 167.11±110.87 hâ ng/mL, respectively. Reference scaling was used because the within-subject standard deviations of the reference product (sWR ) for Cmax and AUC0-t were all higher than the cutoff value of 0.294. The 95% upper confidence bounds were -0.16 and -0.17 for Cmax and AUC0-t , respectively, and the point estimates for the generic/reference product ratio were 1.08 and 1.00, which satisfied the RSABE acceptance criteria of the FDA. The 90% CIs for Cmax and AUC0-t were 90.35%-129.04% and 85.31%-117.15%, respectively, which were within the limits of the EMA for the bioequivalence of 69.84%-143.19% and 80.00%-125.00%.CONCLUSION:
The generic product was bioequivalent to the reference product in terms of the rate and extent of alendronate absorption after a single 70 mg oral dose under fasting conditions.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Alendronato
/
Conservadores da Densidade Óssea
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article